A221805 **EFFECTIVE 3/31/23, at 7am CST, the Phase II portion of the study will permanently close to new patient accrual. Information regarding the status of the Phase III component will be sent upon completion of the Phase II analyses. If the analysis is positive, a reactivation notice will be distributed at the time A221805 opens to Phase III enrollment.**

Study Number: A221805 **EFFECTIVE 3/31/23, at 7am CST, the Phase II portion of the study will permanently close to new patient accrual. Information regarding the status of the Phase III component will be sent upon completion of the Phase II analyses. If the analysis is positive, a reactivation notice will be distributed at the time A221805 opens to Phase III enrollment.**

This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.

Available Sites

• Missouri Baptist Medical Center
• Missouri Baptist Outpatient Center – Sunset Hills
• Missouri Baptist Sullivan Hospital
• Sainte Genevieve County Memorial Hospital
• Parkland Health Center - Farmington

Contact Person(s)

• Brittany Foy 314-996-5888

View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.